AtriCure (ATRC) Scheduled to Post Quarterly Earnings on Tuesday

AtriCure (NASDAQ:ATRC) is scheduled to announce its earnings results after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. AtriCure had a negative return on equity of 14.35% and a negative net margin of 7.98%. The business had revenue of $53.97 million during the quarter, compared to analyst estimates of $52.45 million. During the same period last year, the company earned ($0.31) earnings per share. AtriCure’s quarterly revenue was up 14.9% compared to the same quarter last year. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:ATRC opened at $31.71 on Monday. The company has a current ratio of 4.37, a quick ratio of 3.69 and a debt-to-equity ratio of 0.19. AtriCure has a 1 year low of $26.11 and a 1 year high of $36.49. The stock’s fifty day moving average price is $30.66. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -33.73 and a beta of 0.27.

Several analysts recently issued reports on the company. JPMorgan Chase & Co. set a €78.00 ($90.70) price objective on Porsche Automobil and gave the stock a “neutral” rating in a report on Friday, April 12th. Northland Securities reiterated a “hold” rating on shares of Lendingtree in a report on Friday, April 26th. Zacks Investment Research lowered Phoenix New Media from a “hold” rating to a “sell” rating in a report on Tuesday, July 23rd. BTIG Research assumed coverage on GrubHub in a report on Tuesday, April 2nd. They set a “buy” rating and a $95.00 price objective for the company. Finally, BidaskClub lowered Zai Lab from a “strong-buy” rating to a “buy” rating in a report on Friday. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. AtriCure has a consensus rating of “Buy” and a consensus target price of $36.67.

In other AtriCure news, SVP Justin J. Noznesky sold 10,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the senior vice president now directly owns 94,068 shares of the company’s stock, valued at $2,822,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO M. Andrew Wade sold 9,850 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $30.00, for a total transaction of $295,500.00. Following the transaction, the chief financial officer now directly owns 166,824 shares in the company, valued at $5,004,720. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,554 shares of company stock valued at $1,866,620. 8.00% of the stock is owned by corporate insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

See Also: Current Ratio

Earnings History for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with's FREE daily email newsletter.